戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 o15-4513 binding at the diazepam-insensitive benzodiazepine receptor.
2 -dependent protein kinase and the peripheral benzodiazepine receptor.
3 ear independent of binding to the peripheral benzodiazepine receptor.
4  ligand of the mitochondrial peripheral-type benzodiazepine receptor.
5 ng component of the mitochondrial peripheral benzodiazepine receptor.
6 an antagonist and partial inverse agonist of benzodiazepine receptor.
7 achieve sustained binding equilibrium at the benzodiazepine receptors.
8 e binding of RU34347 to diazepam-insensitive benzodiazepine receptors.
9  receptor in the brain and to peripheral 1,4 benzodiazepine receptors.
10 PET imaging with (18)F-FDG, (18)F-peripheral benzodiazepine receptor ((18)F-PBR), and (18)F-florbetap
11 195) is a ligand specific for the peripheral benzodiazepine receptor abundant on macrophages and is e
12 ventions enabling transitions from long-term benzodiazepine receptor agonist (BZRA) use to cognitive
13 n by bilateral intra-basalis infusion of the benzodiazepine receptor agonist chlordiazepoxide (40 mic
14 ry efficacy outcome was percentage achieving benzodiazepine receptor agonist discontinuation 6 months
15 Compared with SGT, MTcap resulted in greater benzodiazepine receptor agonist discontinuation at 6 mon
16 hanisms improved the percentage of long-term benzodiazepine receptor agonist discontinuation compared
17 targeting placebo effect mechanisms improves benzodiazepine receptor agonist discontinuation.
18 tor agonist use at 1 week posttreatment, and benzodiazepine receptor agonist dose and the Dysfunction
19  interventions, the most evidence exists for benzodiazepine receptor agonist drugs, although persiste
20 el intervention that masks the daily dose of benzodiazepine receptor agonist during tapering and augm
21     Placebo effects are commonly observed in benzodiazepine receptor agonist hypnotic clinical trials
22  Clinical guidelines recommend discontinuing benzodiazepine receptor agonist hypnotics (particularly
23                   A separate concern is that benzodiazepine receptor agonist hypnotics can cause para
24 ileptics, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonist hypnotics, and opioids.
25            Intravenous administration of the benzodiazepine receptor agonist midazolam, resulted in a
26                               The peripheral benzodiazepine receptor agonist PK11195 induced RGC deat
27  We have recently reported that midazolam, a benzodiazepine receptor agonist that is also a short act
28 .67-8.12; P = .001) and reduced frequency of benzodiazepine receptor agonist use (nights/week) at 1 w
29 ntage of participants that have discontinued benzodiazepine receptor agonist use at 1 week posttreatm
30                        Pretreatment with the benzodiazepine receptor agonist, diazepam (5 mg/kg), abo
31                                          The benzodiazepine receptor agonist, midazolam (1 and 2 micr
32 e with beta-carboline, an anxiogenic inverse benzodiazepine receptor agonist, normalized alcohol pref
33                                   The use of benzodiazepine receptor agonists (BZRA) poses serious he
34 ilitation of wake-promoting systems, whereas benzodiazepine receptor agonists (BzRAs) such as zolpide
35                                              Benzodiazepine receptor agonists included zolpidem, zopi
36 to assess the efficacy of benzodiazepines or benzodiazepine receptor agonists or behavioral treatment
37                             Barbiturates and benzodiazepine receptor agonists, for example, both pote
38 diazepines and benzodiazepine-related drugs (benzodiazepine receptor agonists, or BZRAs).
39 ls of self-administration than non-selective benzodiazepine receptor agonists.
40 Insomnia treatments include benzodiazepines, benzodiazepine-receptor agonists, and cognitive behaviou
41 ction of StAR remain unclear; the peripheral benzodiazepine receptor, an OMM protein, appears to be i
42           This suggests an interplay between benzodiazepine receptors and delta-opioid receptors in r
43 istribution volume are consistent with fewer benzodiazepine receptors and/or reduced affinity of rece
44  propofol alone, and in combination with the benzodiazepine receptor antagonist flumazenil, into the
45            Intravenous administration of the benzodiazepine receptor antagonist flumazenil, resulted
46 47 microM, alone and in combination with the benzodiazepine receptor antagonist flumazenil, which has
47  function, the mice were challenged with the benzodiazepine receptor antagonist, flumazenil.
48 keys were prevented by pretreatment with the benzodiazepine receptor antagonist, RO15-1788, which blo
49  fully antagonised by 1 microM flumazenil, a benzodiazepine receptor antagonist.
50 ime-dependent regulation of cortical GABA(A)-benzodiazepine receptors associated with the recovery fr
51  report that Dexras1 binds to the peripheral benzodiazepine receptor-associated protein (PAP7), a pro
52 it was first characterized as the peripheral benzodiazepine receptor because it appears to be respons
53  subjects, a quantitative measure related to benzodiazepine receptor binding (distribution volume) wa
54             Focal increases and decreases in benzodiazepine receptor binding have been demonstrated i
55             No studies have examined central benzodiazepine receptor binding in patients with posttra
56 ose of this study was to examine measures of benzodiazepine receptor binding in PTSD.
57 mals exposed to stress exhibit a decrease in benzodiazepine receptor binding in the frontal cortex.
58 monstrated reduced dopamine D2 and increased benzodiazepine receptor binding in the striatum of HD an
59                                      Reduced benzodiazepine receptor binding is commonly seen at an e
60       These findings of lower values for the benzodiazepine receptor binding measure of distribution
61 To identify potential abnormalities of brain benzodiazepine receptor binding number and distribution
62                               The density of benzodiazepine receptor binding was also increased in th
63 w visualization of a quantitative measure of benzodiazepine receptor binding, are reported to have hi
64 Other agents, such as cyclosporin A and some benzodiazepine receptor-binding agents, have been found
65 adenosine, alone and in combination with the benzodiazepine receptor blocker flumazenil, into the MPA
66 r range, show selectivity toward the central benzodiazepine receptor (BzR) and exhibit structure-affi
67          Increased activation of the central benzodiazepine receptor (BZR) appears to play an importa
68 rontoparietal ACh efflux alone, and with the benzodiazepine receptor (BZR) weak inverse agonist ZK 93
69 ives was designed and synthesized as central benzodiazepine receptor (CBR) ligands.
70 e have previously shown reduction of central benzodiazepine receptor (cBZR) binding restricted to the
71  previously shown that reductions of central benzodiazepine receptors (cBZRs) are restricted to the h
72 outflow of glutamate, and implicate the GABA/benzodiazepine receptor complex in the stress-induced ac
73 h affinity for the gamma-aminobutyric acid A/benzodiazepine receptor complex was developed.
74 ty for the gamma-aminobutyric acid A (GABAA)/benzodiazepine receptor complex with efficacies ranging
75  urea series had high affinity for the GABAA/benzodiazepine receptor complex with varying in vitro ef
76  of chloride channel function in the GABA(A)-benzodiazepine receptor complex, or increases in neurona
77 ce through chloride channels coupled to GABA-benzodiazepine receptor complex.
78 by direct or indirect actions on the GABA(A)-benzodiazepine receptor complex.
79 al seizures, to quantify the GABA(A)-central benzodiazepine receptor complex.
80 his is related to its effects on the GABA(A)-benzodiazepine receptor complex.
81 y a direct or indirect action on the GABA(A)-benzodiazepine receptor complex.
82  in part via agonist-like actions at GABA(A)/benzodiazepine receptor complexes in the ventral tegment
83  returns ligand binding to both the GABA and benzodiazepine receptor components of the GABAA receptor
84                          Cortical mapping of benzodiazepine receptor concentration ([(11) C]FMZ Bmax)
85  in gamma-aminobutyric acid type A (GABA(A))-benzodiazepine receptors contribute to the neurobiology
86                      Alterations in cortical benzodiazepine receptor density have been described in p
87 ntly that regions of increased and decreased benzodiazepine receptor density may be seen in patients
88  positron emission tomography measurement of benzodiazepine receptor density.
89                                              Benzodiazepine receptor distribution volume is significa
90 ography with [11C]flumazenil revealed normal benzodiazepine receptor distribution volumes, similar to
91               Gamma-aminobutyric acid (GABA)/benzodiazepine receptors, dopamine D1-like and D2-like r
92 ACBP required the presence of the peripheral benzodiazepine receptor (for which ACBP is a ligand) to
93 r partial agonist MRK-696, and non-selective benzodiazepine receptor full agonists, midazolam and lor
94                               Alterations in benzodiazepine receptor function in this area may underl
95 he reduced anxiety was due to differences in benzodiazepine receptor function, the mice were challeng
96 ted by ethanol-induced alteration of GABA(A)-benzodiazepine receptor function.
97     They measured the distribution volume of benzodiazepine receptors in 11 recently detoxified patie
98 e characterised the biphasic response of the benzodiazepine receptor inverse agonist RU34347 in the r
99 terial TspO and the mitochondrial peripheral benzodiazepine receptor is discussed.
100 ; TSPO), previously known as peripheral-type benzodiazepine receptor, is a high-affinity cholesterol-
101 n (TSPO), previously known as the peripheral benzodiazepine receptor, is a mitochondrial outer membra
102 PO), previously known as the peripheral-type benzodiazepine receptor, is an outer mitochondrial membr
103 n (TSPO), previously known as the peripheral benzodiazepine receptor, is of longstanding medical inte
104 PO) (18 kDa), formerly called the peripheral benzodiazepine receptor, is upregulated on activated mic
105                               Higher GABA(A)-benzodiazepine receptor levels during acute withdrawal m
106 we used positron emission tomography and the benzodiazepine receptor ligand flumazenil labeled with c
107 PET studies with a gamma-aminobutyric acid A-benzodiazepine receptor ligand, (11)C-flumazenil, and th
108 ecarboxamide (PK11195), a typical peripheral benzodiazepine receptor ligand, has been established as
109  in Pgp(+) AML cells and that the peripheral benzodiazepine receptor ligand, PK11195, sensitizes AML
110 n terms of therapeutic drug design, although benzodiazepine receptor ligands are an example of the se
111                                              Benzodiazepine receptor ligands that bound to the purifi
112 e rat mitochondrial outer membrane-localized benzodiazepine receptor (MBR) was expressed in wild-type
113 hannel (IMAC) modulated by the mitochondrial benzodiazepine receptor (mBzR).
114 pounds exhibit functional selectivity at the benzodiazepine receptor of GABA(A) receptor subtypes.
115 within this series had high affinity for the benzodiazepine receptor on the alpha-aminobutyric acid A
116 icate either a toxic effect of alcoholism on benzodiazepine receptors or a vulnerability factor for d
117                 These results suggest that a benzodiazepine receptor partial agonist may have greater
118 ere compared with those of the non-selective benzodiazepine receptor partial agonist MRK-696, and non
119 ive properties of the novel imidazoquinoline benzodiazepine receptor partial agonist, PNU-101017, in
120 olinesterase inhibitor physostigmine nor the benzodiazepine receptor partial inverse agonist FG 7142
121 ivity in the mPFC and BLA in response to the benzodiazepine receptor partial inverse agonist N-methyl
122 tein that interacts with the peripheral-type benzodiazepine receptor (PBR) and cAMP-dependent protein
123 tein that interacts with the peripheral-type benzodiazepine receptor (PBR) and the cAMP-dependent pro
124    To evaluate the utility of the peripheral benzodiazepine receptor (PBR) as a biomarker of neurotox
125 ir applications as nonradioactive peripheral benzodiazepine receptor (PBR) binding probes and photose
126                               The peripheral benzodiazepine receptor (PBR) has been used as a sensiti
127 he role of the mitochondrial peripheral-type benzodiazepine receptor (PBR) in steroidogenesis, we dev
128                              Peripheral-type benzodiazepine receptor (PBR) is an 18 kDa high-affinity
129                          The peripheral-type benzodiazepine receptor (PBR) is an Mr 18,000 protein pr
130 ts suggest that the mitochondrial peripheral benzodiazepine receptor (PBR) is not the cellular bindin
131 -carboxamide (PK11195), a typical peripheral benzodiazepine receptor (PBR) ligand, as a selective and
132                               The peripheral benzodiazepine receptor (pBR) ligand, PK11195, promotes
133 tiapoptotic mitochondrial protein peripheral benzodiazepine receptor (PBR) protects neonatal mice aga
134 the carboxyl terminus of the peripheral-type benzodiazepine receptor (PBR), an outer mitochondrial me
135 otein (TSPO), also referred to as peripheral benzodiazepine receptor (PBR), is a crucial 18-kDa outer
136  binding site, the so-called peripheral-type benzodiazepine receptor (PBR).
137 ator protein 18 kDa [TSPO or peripheral-type benzodiazepine receptor (PBR)] was identified in the sea
138                Elevated levels of peripheral benzodiazepine receptors (PBR) are associated with activ
139 ds for sensitive imaging of brain peripheral benzodiazepine receptors (PBR) in vivo.
140                                   Peripheral benzodiazepine receptors (PBRs) are located on the outer
141 ly developed radioligand to image peripheral benzodiazepine receptors (PBRs) in brain.
142 ), an antagonist to mitochondrial peripheral benzodiazepine receptors (PBRs), with bortezomib trigger
143                                   Peripheral benzodiazepine receptor (PBzR) agonists (PK11195, FGIN 1
144  photon emission computed tomography and the benzodiazepine receptor radiotracer [123I]iomazenil.
145 in (TSPO; previously known as the peripheral benzodiazepine receptor) remains unclear because its pre
146 ex II, voltage-dependent anion channels, and benzodiazepine receptor, respectively.
147 sitron-emitting ligand that binds peripheral benzodiazepine receptor sites in activated microglia--us
148  emission topography (PET) ligand peripheral benzodiazepine receptor standardized uptake values (PBR2
149 pha5beta3gamma2, and alpha6beta3gamma2 GABAA/benzodiazepine receptor subtypes are reported.
150 erial homolog of the mammalian mitochondrial benzodiazepine receptor, the tryptophan-rich sensory pro
151  (TSPO), previously known as peripheral-type benzodiazepine receptor; the TSPO-associated protein PAP
152             [3H]Flunitrazepam binding to the benzodiazepine receptor was enhanced by ammonium (10-500
153 Ro 15-1788 and [3H]Ro 15-4513 binding to the benzodiazepine receptor was not significantly enhanced b
154 tor with selectivity for the type-I (omega1) benzodiazepine receptor, was studied for efficacy in alt
155 lium has neither GABA(A) nor peripheral-type benzodiazepine receptors, we find that both a diazepam b
156                                         GABA/benzodiazepine receptors were unchanged either before or

 
Page Top